Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

Completed · Phase 2

Conditions studied: Glioblastoma Multiforme

In brief

This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients. The primary objective will be to determine the efficacy of Avastin (bevacizumab) and metronomic temozolomide in malignant glioma patients. The secondary objective will be to determine the safety of Avastin, 10 mg/kg every other week, in combination with metronomic temozolomide in terms of progression-free survival.

Key facts

Study ID
NCT00501891
Run by
Duke University
People needed
32
Starts
2007-07-01
Expected to finish
2009-11-01
Last updated by the study team
2013-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.